Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria

[1]  R. Echols,et al.  Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects , 2021, Journal of clinical pharmacology.

[2]  F. Pea,et al.  A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol. , 2021, Journal of global antimicrobial resistance.

[3]  U. Fuhr,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol , 2021, Clinical Pharmacokinetics.

[4]  S. Di Bella,et al.  The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases , 2021, Antibiotics.

[5]  M. Bassetti,et al.  Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data , 2020, Infection and drug resistance.

[6]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[7]  Y. -. Lee,et al.  Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety , 2020, Clinical Drug Investigation.

[8]  D. Livermore,et al.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline , 2020, Antimicrobial Agents and Chemotherapy.

[9]  D. Marriott,et al.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# , 2020, Intensive Care Medicine.

[10]  A. McAdam,et al.  What’s Special about Cefiderocol? A Micro-Comic Strip , 2020, Journal of Clinical Microbiology.

[11]  J. Pogue,et al.  Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms , 2020, Infectious Diseases and Therapy.

[12]  R. Echols,et al.  Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Rio Nakamura,et al.  In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models , 2019, Antimicrobial Agents and Chemotherapy.

[14]  Richard J. Goater,et al.  Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread , 2019, Nature Microbiology.

[15]  H. Yoshizawa,et al.  Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship. , 2018, European journal of medicinal chemistry.

[16]  R. Martin,et al.  Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae , 2018, Front. Cell. Infect. Microbiol..

[17]  T. Nishikawa,et al.  In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria , 2017, Antimicrobial Agents and Chemotherapy.

[18]  M. Hackel,et al.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study) , 2017, Antimicrobial Agents and Chemotherapy.

[19]  R. Echols,et al.  Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment , 2016, Journal of clinical pharmacology.

[20]  R. Bellomo,et al.  Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. , 2016, American journal of respiratory and critical care medicine.

[21]  K. Tateda,et al.  Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases , 2016, Antimicrobial Agents and Chemotherapy.

[22]  F. Taccone,et al.  Understanding PK/PD , 2016, Intensive Care Medicine.

[23]  A. Oliver,et al.  Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved? , 2014, Enfermedades infecciosas y microbiologia clinica.

[24]  S. Blot,et al.  The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. , 2014, Advanced drug delivery reviews.

[25]  J. Rello,et al.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[27]  J. Roberts,et al.  Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations? , 2013, Antimicrobial Agents and Chemotherapy.

[28]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  M. Roberts,et al.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. , 2009, The Journal of antimicrobial chemotherapy.

[30]  A. Gous,et al.  Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. , 2005, International journal of antimicrobial agents.

[31]  J. Gums,et al.  The Changing Face of Antibiotic Prescribing: The Mutant Selection Window , 2004, The Annals of pharmacotherapy.

[32]  Robyn Norton,et al.  A comparison of albumin and saline for fluid resuscitation in the Intensive Care unit , 2005 .

[33]  K. Bowker,et al.  Continuous Infusion of β-Lactam Antibiotics , 1998 .

[34]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[35]  J. A. Kruse,et al.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections , 1996, Antimicrobial agents and chemotherapy.

[36]  D. M. Ryan.  Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. , 1993, The Journal of antimicrobial chemotherapy.

[37]  P. Shah,et al.  Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus , 1976 .